Recent Updates
Recently added Catalysts
CDNA Positive Sentiment

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CareDx, Inc. presented new data at ASN Kidney Week 2026 linking elevated AlloSure® Kidney levels to nearly three times the risk of adverse graft outcomes in patients with borderline rejection or TCMR. This finding addresses critical challenges in kidney transplant management. The event took place from October 22-25 in Denver, Colorado.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data presented at ASN Kidney Week 2026.
  • Link between elevated AlloSure® Kidney and graft outcomes.
  • Potential to improve kidney transplant management.

Full Press Release Details

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado. The findings address several persistent challenges in kidney transplant management: determining the significance of a

Frequently Asked Questions

What did CareDx present at ASN Kidney Week 2026?

CareDx presented data linking elevated AlloSure® Kidney to higher graft risks.

What is AlloSure® Kidney?

AlloSure® Kidney measures donor-derived cell-free DNA in transplant patients.

What risk is associated with elevated AlloSure® levels?

Elevated levels are linked to nearly three-fold higher risk of adverse graft outcomes.

When did ASN Kidney Week 2026 take place?

The event occurred from October 22 to 25, 2026, in Denver, Colorado.

ShareAdd on Google
Tags: CDNA CareDx AlloSure kidney transplant ASN Kidney Week graft outcomes
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$374M liquidity · $0M/mo burn
Low dilution risk